These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 10954271)
1. Discrimination between neoplastic and nonneoplastic brain lesions by use of proton MR spectroscopy: the limits of accuracy with a logistic regression model. Butzen J; Prost R; Chetty V; Donahue K; Neppl R; Bowen W; Li SJ; Haughton V; Mark L; Kim T; Mueller W; Meyer G; Krouwer H; Rand S AJNR Am J Neuroradiol; 2000 Aug; 21(7):1213-9. PubMed ID: 10954271 [TBL] [Abstract][Full Text] [Related]
2. Accuracy of single-voxel proton MR spectroscopy in distinguishing neoplastic from nonneoplastic brain lesions. Rand SD; Prost R; Haughton V; Mark L; Strainer J; Johansen J; Kim TA; Chetty VK; Mueller W; Meyer G; Krouwer H AJNR Am J Neuroradiol; 1997 Oct; 18(9):1695-704. PubMed ID: 9367317 [TBL] [Abstract][Full Text] [Related]
3. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas. Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868 [TBL] [Abstract][Full Text] [Related]
4. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury. Elias AE; Carlos RC; Smith EA; Frechtling D; George B; Maly P; Sundgren PC Acad Radiol; 2011 Sep; 18(9):1101-8. PubMed ID: 21820634 [TBL] [Abstract][Full Text] [Related]
5. Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors. Server A; Josefsen R; Kulle B; Maehlen J; Schellhorn T; Gadmar Ø; Kumar T; Haakonsen M; Langberg CW; Nakstad PH Acta Radiol; 2010 Apr; 51(3):316-25. PubMed ID: 20092374 [TBL] [Abstract][Full Text] [Related]
6. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Law M; Yang S; Wang H; Babb JS; Johnson G; Cha S; Knopp EA; Zagzag D AJNR Am J Neuroradiol; 2003; 24(10):1989-98. PubMed ID: 14625221 [TBL] [Abstract][Full Text] [Related]
7. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. Smith EA; Carlos RC; Junck LR; Tsien CI; Elias A; Sundgren PC AJR Am J Roentgenol; 2009 Feb; 192(2):W45-52. PubMed ID: 19155380 [TBL] [Abstract][Full Text] [Related]
8. Can proton MR spectroscopic and perfusion imaging differentiate between neoplastic and nonneoplastic brain lesions in adults? Hourani R; Brant LJ; Rizk T; Weingart JD; Barker PB; Horská A AJNR Am J Neuroradiol; 2008 Feb; 29(2):366-72. PubMed ID: 18055564 [TBL] [Abstract][Full Text] [Related]
9. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. Zeng QS; Li CF; Zhang K; Liu H; Kang XS; Zhen JH J Neurooncol; 2007 Aug; 84(1):63-9. PubMed ID: 17619225 [TBL] [Abstract][Full Text] [Related]
10. Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling. Huang J; Wang AM; Shetty A; Maitz AH; Yan D; Doyle D; Richey K; Park S; Pieper DR; Chen PY; Grills IS Magn Reson Imaging; 2011 Sep; 29(7):993-1001. PubMed ID: 21571478 [TBL] [Abstract][Full Text] [Related]
11. [Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors]. Lichy MP; Bachert P; Hamprecht F; Weber MA; Debus J; Schulz-Ertner D; Schlemmer HP; Kauczor HU Rofo; 2006 Jun; 178(6):627-33. PubMed ID: 16703499 [TBL] [Abstract][Full Text] [Related]
12. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. Floeth FW; Pauleit D; Wittsack HJ; Langen KJ; Reifenberger G; Hamacher K; Messing-Jünger M; Zilles K; Weber F; Stummer W; Steiger HJ; Woebker G; Müller HW; Coenen H; Sabel M J Neurosurg; 2005 Feb; 102(2):318-27. PubMed ID: 15739561 [TBL] [Abstract][Full Text] [Related]
13. Multimodal MRI in the characterization of glial neoplasms: the combined role of single-voxel MR spectroscopy, diffusion imaging and echo-planar perfusion imaging. Zonari P; Baraldi P; Crisi G Neuroradiology; 2007 Oct; 49(10):795-803. PubMed ID: 17619871 [TBL] [Abstract][Full Text] [Related]
14. Brain tumors: localized H-1 MR spectroscopy at 0.5 T. Prost R; Haughton V; Li SJ Radiology; 1997 Jul; 204(1):235-8. PubMed ID: 9205253 [TBL] [Abstract][Full Text] [Related]
15. Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses. Majós C; Aguilera C; Alonso J; Julià-Sapé M; Castañer S; Sánchez JJ; Samitier A; León A; Rovira A; Arús C AJNR Am J Neuroradiol; 2009 Mar; 30(3):544-51. PubMed ID: 19095788 [TBL] [Abstract][Full Text] [Related]
16. Effect of voxel position on single-voxel MR spectroscopy findings. Ricci PE; Pitt A; Keller PJ; Coons SW; Heiserman JE AJNR Am J Neuroradiol; 2000 Feb; 21(2):367-74. PubMed ID: 10696025 [TBL] [Abstract][Full Text] [Related]
17. The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: A systematic review and meta-analysis. Wang Q; Zhang H; Zhang J; Wu C; Zhu W; Li F; Chen X; Xu B Eur Radiol; 2016 Aug; 26(8):2670-84. PubMed ID: 26471274 [TBL] [Abstract][Full Text] [Related]
18. Cutoff value of choline concentration reliably reveals high-grade brain tumors among other contrast-enhancing brain lesions. Porto L; Hattingen E; Stuecher A; Herminghaus S; Lanfermann H; Ulrich Pilatus UP J Neurol Surg A Cent Eur Neurosurg; 2012 May; 73(3):147-52. PubMed ID: 22190143 [TBL] [Abstract][Full Text] [Related]
19. Utility of proton MR spectroscopy for differentiating typical and atypical primary central nervous system lymphomas from tumefactive demyelinating lesions. Lu SS; Kim SJ; Kim HS; Choi CG; Lim YM; Kim EJ; Kim DY; Cho SH AJNR Am J Neuroradiol; 2014 Feb; 35(2):270-7. PubMed ID: 23928144 [TBL] [Abstract][Full Text] [Related]
20. Differentiation of glioblastoma multiforme from metastatic brain tumor using proton magnetic resonance spectroscopy, diffusion and perfusion metrics at 3 T. Tsougos I; Svolos P; Kousi E; Fountas K; Theodorou K; Fezoulidis I; Kapsalaki E Cancer Imaging; 2012 Oct; 12(3):423-36. PubMed ID: 23108208 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]